Wainua (Eplontersen Sodium) Patent Expiration, LOE Window & CMS Spending

Wainua (Eplontersen Sodium) by AstraZeneca: FDA Orange Book core substance LOE 2034-08-25, 0 AB generics, $59.9M 2024 CMS Part D & Medicaid spend, and $42,831 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN217388 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-08-25
Last Listed Patent or Exclusivity Date2034-08-25
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$59.9M
2024 Medicare Part D Spend$56.9M
2024 Medicaid Spend$3.1M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($42,831 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.